REV-MED recently showcased its innovative cell regeneration therapy systems and laser medical devices at Arab Health 2023 in Dubai, UAE.
Celebrating its 48th year, Arab Health is the largest medical device exhibition in the Middle East. This year’s event, held through February 2, featured over 4,000 companies from 68 countries and attracted more than 130,000 visitors.
At the exhibition, REV-MED presented:
- TriCell: A system for autologous stem cell therapy
- Hithera 4.0: A laser medical device aiding cell regeneration
- OnyRay: A laser device for treating onychomycosis (nail fungus)
Ahead of the event, REV-MED organized a Hithera 4.0 workshop in Dubai with seven medical experts representing India, Jordan, UAE, and Türkiye. This session facilitated the exchange of medical insights, techniques, and innovations.
According to REV-MED, Hithera 4.0 safely delivers laser treatment to deep tissues without causing burns or injuries. Using specialized laser wavelengths, it provides anti-inflammatory, pain relief, and swelling absorption effects, making it effective for joint, muscle, and bone damage treatments.
During the exhibition, REV-MED engaged with over 400 companies from 25 countries, including Germany, Italy, Switzerland, Greece, Spain, Türkiye, and GCC countries. The company actively discussed tailored sales strategies and secured exclusive export agreements for major markets in the Middle East and North Africa (MENA) region.
CEO Bongkeun Shin expressed his optimism, stating, “Despite the challenges of market expansion during the COVID-19 pandemic, this exhibition yielded significant achievements. We aim to establish 2023 as a pivotal year for REV-MED, marked by FDA approval for U.S. entry and IPO preparation.”
Founded in 2009, REV-MED specializes in bio-kits for concentrating and extracting growth and regenerative factors from blood, bone marrow, and adipose tissue. The company continues its commitment to the development and commercialization of autologous blood concentration systems for stem cell therapy.
Source: HealthTrends (http://www.k-health.com)
REV-MED recently showcased its innovative cell regeneration therapy systems and laser medical devices at Arab Health 2023 in Dubai, UAE.
Celebrating its 48th year, Arab Health is the largest medical device exhibition in the Middle East. This year’s event, held through February 2, featured over 4,000 companies from 68 countries and attracted more than 130,000 visitors.
At the exhibition, REV-MED presented:
Ahead of the event, REV-MED organized a Hithera 4.0 workshop in Dubai with seven medical experts representing India, Jordan, UAE, and Türkiye. This session facilitated the exchange of medical insights, techniques, and innovations.
According to REV-MED, Hithera 4.0 safely delivers laser treatment to deep tissues without causing burns or injuries. Using specialized laser wavelengths, it provides anti-inflammatory, pain relief, and swelling absorption effects, making it effective for joint, muscle, and bone damage treatments.
During the exhibition, REV-MED engaged with over 400 companies from 25 countries, including Germany, Italy, Switzerland, Greece, Spain, Türkiye, and GCC countries. The company actively discussed tailored sales strategies and secured exclusive export agreements for major markets in the Middle East and North Africa (MENA) region.
CEO Bongkeun Shin expressed his optimism, stating, “Despite the challenges of market expansion during the COVID-19 pandemic, this exhibition yielded significant achievements. We aim to establish 2023 as a pivotal year for REV-MED, marked by FDA approval for U.S. entry and IPO preparation.”
Founded in 2009, REV-MED specializes in bio-kits for concentrating and extracting growth and regenerative factors from blood, bone marrow, and adipose tissue. The company continues its commitment to the development and commercialization of autologous blood concentration systems for stem cell therapy.
Source: HealthTrends (http://www.k-health.com)